Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
09 août 2022 16h02 HE
|
Vir Biotechnology, Inc.
– More than $2.6 billion in cash, cash equivalents, investments and profit-share payments to be received from GSK expected to fund the company’s ongoing operations and liabilities for up to five years...
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2022 Financial Results on August 4, 2022
21 juil. 2022 16h05 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter...
Vir Biotechnology Announces Transition of Chief Scientific Officer
14 juil. 2022 08h30 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, July 14, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Herbert “Skip” Virgin, M.D., Ph.D., Vir’s executive vice president, research and chief...
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
25 juin 2022 07h00 HE
|
Vir Biotechnology, Inc.
– Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals – ...
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022
08 juin 2022 07h34 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B virus (HBV) program have been...
Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details
18 mai 2022 16h03 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2022 Annual General Meeting of Stockholders on Friday, May 20,...
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
05 mai 2022 16h07 HE
|
Vir Biotechnology, Inc.
– $1.2 billion of sotrovimab collaboration revenue recognized in the first quarter – – More than $2.5 billion in cash, cash equivalents, investments and collaboration receivables at the end of the...
Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day
27 avr. 2022 08h39 HE
|
Vir Biotechnology, Inc.
– Strategic clinical program for hepatitis B and D with potential for multiple value drivers in 2022 –– Virtual R&D Day webcast scheduled for today, Wednesday, April 27, at 12:00 pm ET / 9:00...
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022
21 avr. 2022 16h05 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, April 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter...
Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day
13 avr. 2022 16h02 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, April 13, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will host a virtual Hepatitis Portfolio R&D Day for the investment...